NCT04602624View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 7, 2020

Primary Completion Date

September 28, 2021

Study Completion Date

September 28, 2021

Conditions
Alzheimer DiseaseCognitive DysfunctionMild Dementia
Interventions
DRUG

SAGE-718

SAGE-718 oral tablets.

Trial Locations (10)

20877

Sage Investigational Site, Gaithersburg

30030

Sage Investigational Site, Decatur

30033

Sage Investigational Site, Decatur

33137

Sage Investigational Site, Miami

33713

Sage Investigational Site, St. Petersburg

44720

Sage Investigational Site, North Canton

48334

Sage Investigational Site, Farmington Hills

68130

Sage Investigational Site, Omaha

85044

Sage Investigational Site, Phoenix

92374

Sage Investigational Site, Redlands

All Listed Sponsors
lead

Supernus Pharmaceuticals, Inc.

INDUSTRY

NCT04602624 - A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD) | Biotech Hunter | Biotech Hunter